AAD 2023: Long-Term Immune-Related Adverse Events After Adjuvant Anti-PD-1 Therapy Characterized in Patients With Melanoma
Nearly one in three cases of cutaneous toxicities will become chronic
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.